Home›Stock Screener›Syncom Formulations

Syncom Formulations Share Price Today | Stock Price & Syncom Formulations Share Screener

SYNCOMF Pharmaceuticals & Biotechnology
Live Share Price NSE
₹22.08
▲ 1.19 (5.70%)
2026-11-18 00:00:00
Live Share Price BSE
₹22.06
▲ 1.16 (5.55%)
2026-11-18 00:00:00

As of November 18, 2026, the live Syncom Formulations share price (NSE: SYNCOMF) is ₹22.08 on NSE and ₹22.06 on BSE, up 5.70% from the previous close, with shares trading between ₹20.78 and ₹22.90 in today's trading session, and a 52-week range of ₹10.30–₹26.18. Track SYNCOMF market capitalization to gauge the company's total market size. Use the Syncom Formulations stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Syncom Formulations opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹148 and net income of ₹27, with EBITDA of ₹38, an operating margin of 22.0% and a profit margin of 18.2%.

Syncom Formulations Market Cap ₹1,907.26 Cr.
SYNCOMF P/E Ratio (TTM) 22.30
Syncom Formulations P/B Ratio 4.59
EPS (TTM) ₹0.81
Dividend Yield 0.49%
Debt to Equity 0.01
SYNCOMF 52 Week High ₹26.18
Syncom Formulations 52 Week Low ₹10.30
Operating Margin 22.00%
Profit Margin 18.24%
SYNCOMF Revenue (TTM) ₹148.00
EBITDA ₹38.00
Net Income ₹27.00
Total Assets ₹534.00
Total Equity ₹415.00

Syncom Formulations Share Price Chart

Track the current stock price of Syncom Formulations with an interactive chart. Analyse SYNCOMF share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Syncom Formulations stock quote in one place.

The quote of ₹22.08 sits between the 52-week low of ₹10.30 and the 52-week high of ₹26.18, and the latest session moved 5.70% from the previous close.

Syncom Formulations Company Profile - Fundamental Screener

Screen Syncom Formulations company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SYNCOMF shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE312C01025.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE312C01025

Syncom Formulations Balance Sheet Screener

Screen SYNCOMF balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹534, up from ₹413 in 2025.

Latest statistics put total assets at ₹534 and shareholder funds at ₹415, with a leverage ratio of 0.01.

Item 2026 2025 2024 2023 2022 2017 2016 2015

Assets

Total Assets 534 413 405 378 308 180 175 138
Current Assets 0 0 0 0 0 0 0 0
Fixed Assets 184 125 120 91 94 55 46 46

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0
Current Liabilities 15 12 10 9 8 8 6 6
Non-Current Liabilities 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 415 342 288 256 222 117 109 100
Share Capital 94 94 94 94 86 78 78 78
Reserves & Surplus 321 248 194 162 131 39 31 22

Syncom Formulations Income Statement Screener - Profit & Revenue Analysis

Screen Syncom Formulations income statement and profit fundamentals. Analyze SYNCOMF quarterly results. Syncom Formulations reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹148 and net profit was ₹27, equal to earnings per unit of ₹0.28, at an operating margin of 22%.

In that period expenses were ₹110, interest cost ₹0 and tax ₹9. The next period listed, 2026-Jun, shows revenue of ₹133 and net profit of ₹25.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 148 133 150 121 127 123 156 132 107 89 78 70 68 62 68
Expenses 110 99 113 94 103 101 131 113 90 77 65 58 57 53 55

Operating Costs and Margins

EBITDA 38 34 37 27 24 22 25 19 16 12 13 12 10 8 13
Operating Profit % 22.00% 21.00% 16.00% 18.00% 15.00% 14.00% 12.00% 12.00% 12.00% 12.00% 13.00% 11.00% 10.00% 11.00% 10.00%
Depreciation 2 2 3 1 1 1 1 1 1 1 1 2 1 1 1
Interest 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1

Profit and Earnings

Profit Before Tax 36 32 34 25 22 20 23 17 15 10 10 9 8 6 10
Tax 9 7 9 6 5 5 6 4 4 3 3 2 2 2 2
Net Profit 27 25 25 19 17 16 18 13 11 8 7 7 7 4 9
EPS 0.28 0.26 0.27 0.20 0.18 0.21 0.19 0.14 0.16 0.11 0.10 0.09 0.08 0.07 0.10

Syncom Formulations Cash Flow Screener - Liquidity Fundamentals

Screen SYNCOMF cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹58, and net cash flow was an inflow of ₹4.

Over the same period, investing activities used ₹51 and financing activities used ₹3.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2017-March 2016-March 2015-March

Cash from Operations and Investing

Operating Activities 58 23 -6 11 16 14 24 0
Investing Activities -51 -18 83 -45 -27 -18 -23 1

Financing and Net Cash

Financing Activities -3 -68 -15 35 8 5 -2 1
Net Cash Flow 4 -63 63 1 -3 1 -1 2

Syncom Formulations Shareholding Pattern Screener

See Syncom Formulations shareholding pattern with promoter, FII, and DII holdings. Check Syncom Formulations promoter holding and ownership changes for SYNCOMF on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 50.57%, foreign institutions 2.22%, domestic institutions 0.00% and the public 42.37%, spread across 418,465 shareholders.

The shareholder count was 418,465 in 2026-Sept, compared with 422,114 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57%

Institutional Investors

FII Holding 2.22% 0.35% 0.21% 0.26% 0.10% 0.41% 0.11% 0.13%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 42.37% 44.90% 45.15% 45.04% 45.21% 44.83% 45.20% 45.06%
Other Holding 4.83% 4.18% 4.06% 4.13% 4.12% 4.19% 4.12% 4.24%
Shareholder Count 418,465 422,114 431,690 442,280 457,364 471,066 484,529 489,520

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Syncom Formulations. Syncom Formulations dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.10 per unit for 2026-March, a yield of 0.49%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.10, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.10 0.49%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.03 0.50%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.02 2.06%

Syncom Formulations Stock Index Membership - Nifty & Sensex

See which indices include Syncom Formulations stock. Check SYNCOMF index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 2 indices, including BSE INDEX BSE HC.

Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE INDEX BSE HC
BSE INDEX SMLCAP

Syncom Formulations Market Events Screener - Corporate Actions

Get Syncom Formulations corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Syncom Formulations stock events that may affect SYNCOMF share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 13, 2026, with a record date of November 13, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Dividend dated September 23, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-13 2026-11-13 Quarterly Result Announcement NA 6.24%
2026-09-30 2026-09-30 Annual General Meeting NA 83.54%
2026-09-23 2026-09-23 Dividend ₹ 0.10 /share 42.26%
2026-08-11 2026-08-11 Quarterly Result Announcement NA 7.42%
2026-05-22 2026-05-22 Quarterly Result Announcement NA 5.16%
2026-02-12 2026-02-12 Quarterly Result Announcement NA 6.51%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -0.62%
2025-09-29 2025-09-29 Annual General Meeting NA -8.54%
2025-08-08 2025-08-08 Quarterly Result Announcement NA -0.72%
2025-05-19 2025-05-19 Quarterly Result Announcement NA 6.39%
2025-02-10 2025-02-10 Quarterly Result Announcement NA 0.00%
2024-11-11 2024-11-11 Quarterly Result Announcement NA -1.63%
2024-09-30 2024-09-30 Annual General Meeting NA -5.18%
2023-09-26 2023-09-26 Annual General Meeting NA -7.00%
2022-09-09 2022-09-13 Dividend ₹ 0.03 /share 0.00%

Syncom Formulations Competitors Screener - Peer Stocks Comparison

Screen SYNCOMF competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Syncom Formulations Company Announcements - News & Reports Screener

Screen SYNCOMF latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 18, 2026.

The next most recent announcements are dated November 17, 2026 and November 17, 2026.

Date Update Actions
2026-11-18 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-17 Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Pursuant To Regulation 33(3) Of The SEBI (LODR) Regulations 2015 -
2026-11-17 Board Meeting Outcome for Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Pursuant To Regulation 33(3) Of The SEBI (LODR) Regulations 2015. -
2026-11-04 Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations 2015 Read With SEBI (PIT) Regulations 2015 Regarding Intimation Of Holding The 3/2026-27 Board Meeting Scheduled To Be Held On Friday 13Th Day Of November 2026 -
2026-10-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-01 Announcement under Regulation 30 (LODR)-Dividend Updates -
2026-10-01 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-01 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-10-01 Declaration Of Voting Results -
2026-09-30 Proceedings Of The 38Thannual General Meeting -
2026-09-26 Announcement under Regulation 30 (LODR)-Dividend Updates -
2026-09-24 Closure of Trading Window -
2026-09-18 Corporate Announcement/Information Under Regulation 42 Of SEBI (LODR) Regulations 2015 Regarding Record Date. -
2026-09-08 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-07 Regulation 36(1)(B) Of The SEBI (LODR) Regulations 2015- Dispatch Of Letters To Shareholders Who Have Not Registered Their Email Addresses. -
2026-09-07 Business Responsibility and Sustainability Reporting (BRSR) -
2026-09-07 Submission Of The Notice Of 38Th Annual General Meeting To Be Held On Wednesday 30Th September 2026. -
2026-09-07 Reg. 34 (1) Annual Report. -
2026-09-01 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹22.08, within a 52-week range of ₹10.30 to ₹26.18. The P/E ratio is 22.30 and the P/B ratio is 4.59, with earnings per unit of ₹0.81. Market capitalisation stands at ₹1,907.26 Cr and the dividend yield is 0.49%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.